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ABSTRACT
End-stage renal disease (ESRD) is deﬁned as the inability
of the kidneys to remove waste products and excess
ﬂuid from the blood. ESRD progresses from earlier
stages of chronic kidney disease (CKD) and occurs
when the glomerular ﬁltration rate (GFR) is below 15
ml/minute/1.73 m
2. CKD and ESRD are dramatically ris-
ing due to increasing aging population, population demo-
graphics, and the growing rate of diabetes and
hypertension. Identiﬁcation of multipotential stem/progen-
itor populations in mammalian tissues is important for
therapeutic applications and for understanding develop-
mental processes and tissue homeostasis. Progenitor pop-
ulations are ideal targets for gene therapy, cell
transplantation, and tissue engineering. The demand for
kidney progenitors is increasing due to severe shortage
of donor organs. Because dialysis and transplantation are
currently the only successful therapies for ESRD, cell
therapy offers an alternative approach for kidney dis-
eases. However, this approach may be relevant only in
earlier stages of CKD, when kidney function and histol-
ogy are still preserved, allowing for the integration of
cells and/or for their paracrine effects, but not when
small and ﬁbrotic end-stage kidneys develop. Although
blood- and bone marrow-derived stem cells hold a thera-
peutic promise, they are devoid of nephrogenic potential,
emphasizing the need to seek kidney stem cells beyond
known extrarenal sources. Moreover, controversies
regarding the existence of a true adult kidney stem cell
highlight the importance of studying cell-based therapies
using pluripotent cells, progenitor cells from fetal kidney,
or dedifferentiated/reprogrammed adult kidney cells.
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THE CLINICAL PROBLEM
The prevalence of chronic kidney disease (CKD) and end-
stage renal disease (ESRD) is dramatically increasing [1], and
at the same time, the Medicare cost of ESRD has risen from
$12.2 in 2000 to $20.8 billion in 2007 [2]. ESRD is incurable,
requiring renal replacement therapy, that is, dialysis or pref-
erably renal transplantation. However, the shortage of avail-
able organs for transplantation continues to severely limit this
option [3].
How can organ shortage be combated? In general, supply
of organs can be increased, or their demand can be decreased.
When considering cell replacement in diseased kidneys
via cell transfer, one should carefully dissect the timing of
such a therapy, as end-stage kidneys are already small and
ﬁbrotic and would therefore not allow for the incorporation of
cells or for their paracrine effects. Thus, late CKD stages war-
rant whole kidney replacement, independent of the native kid-
neys, leading to a need for increased organ supply. Accord-
ingly, we have previously demonstrated that stage-speciﬁc
human and porcine embryonic kidney tissue can remarkably
grow, differentiate, and undergo vascularization, achieving
successful organogenesis of urine-producing miniature kid-
neys in immuno-deﬁcient animals [4–6]. The ‘‘growing kid-
neys’’ concept is suggested to be applicable to ESRD as
whole kidney replacement, affording an additional source of
kidney tissue [5]. Other approaches include porcine organ
xenografts [7] or bioengineering of histocompatible renal
units [8]. In the case of whole kidney replacement by generat-
ing kidneys de novo, the generated organ will have to produce
sufﬁcient glomerular ﬁltration rate (GFR) to support body ho-
meostasis. As this is a difﬁcult task, it will likely be easier to
approach organ shortage by decreasing organ demand.
Unlike ESRD, earlier stages of CKD, when residual func-
tion and histology are partially preserved, are expected to be
more suitable for cell therapy, aiming at halting progression
of CKD to ESRD. In this scenario, progressive kidney dam-
age/ﬁbrosis may lead to demands on healthy segments, creat-
ing a pathway of unrelenting damage over time. However, the
tempo of decline may be decreased by serial interventions.
Stem cells, able to self-renew and to intervene in building/
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are especially attractive for such a purpose.
Because CKD is composed of multiple etiologies in which
different kidney cell types are affected (glomerular and tubu-
lar epithelium, glomerular and peri-tubular capillaries, intersti-
tial cells), deﬁning the effect of speciﬁc stem cells on a par-
ticular mature cell type can link various modes of cell therapy
to diverse clinical applications. For instance, podocyte loss in
many glomerular diseases, such as focal segmental glomerulo-
sclerosis, persistent peri-tubular endothelial injury and dys-
function in the hemolytic uremic syndrome, and proteinuric
states (for which proximal tubular cells are especially suscep-
tible), are likely to beneﬁt from different types of stem/pro-
genitor cells. However, this categorization may become irrele-
vant once all etiologies succumb to the common pathological
ﬁnal pathway of progressive renal injury [9].
DEVELOPMENTAL NEPHROLOGY AS A BASIS
FOR THERAPEUTIC APPLICATIONS
The metanephros, the mature mammalian kidney, is formed via
reciprocally inductive interactions between two precursor tis-
sues, which are derived from the intermediate mesoderm (IM),
that is, the metanephric mesenchyme (MM) and the ureteric
bud (UB), a derivative of the Wolfﬁan duct [10, 11]. This com-
plex process is summarized in Figure 1. MM cells that conden-
sate and maintain themselves at the tips of the UB, giving off
cells that differentiate into nephrons [12], are especially impor-
tant. Recent experiments [13–16] have established that these
progenitor cells in the condensed or cap mesenchyme (CM) ful-
ﬁll the criteria of a true committed stem cell, capable of self-
renewing and differentiating into different types of nephron epi-
thelia. Prior to UB induction, the CM expresses a unique com-
bination of transcription factors, including the Hox11 paralogs,
Osr1, Pax2, Eya1, Wt1, Six2, Sall1,a n dCited1 [10], considered
early markers of kidney progenitor cells (Fig. 1). Among these
markers, it was shown that continued expression of Six2 is
required for self-renewal of this stem cell population as nephro-
genesis continues (Fig. 2) [15]. Interestingly, Osr1 has been
recently shown to mark an even earlier lineage in the IM, capa-
ble of giving rise to all metanephric cell components, including
the Six2þ epithelial nephron progenitors, renal vasculature, and
smooth muscle cells [16]. Notably, silencing of most of these
genes coincides with termination of nephrogenesis (human,
34th gestational week; mice, 2 weeks postnatal) [18, 19]. As a
result, endowment of new nephrons is restricted to prenatal de-
velopment in humans, and to the ﬁrst 2 weeks after birth in
rodents [20]. Therefore, the ultimate goal of renal regenerative
medicine is to isolate and/or create an unlimited supply of
human cells resembling the renal progenitors residing in the
Figure 1. Kidney development. (A): The kidney is formed via reciprocal interactions between two precursor tissues derived form the intermediate
mesoderm: the Wolfﬁan duct and the MM. (B): MM-derived signals, mainly the glial-derived neurotrphic factor, induce an outgrowth from the
Wolfﬁan duct, termed the UB. The UB then invades the MM and secretes WNT9b, thereby attracting MM cells. (C): MM cells condense around
the tips of the branching UB, forming the condensed or CM. The CM expresses a unique combination of genes (red) and the mesenchymal marker,
vimentin. The CM contains the kidney stem cells and is capable of self-renewal. In response to UB signals, CM cells start to produce WNT4, which
acts in an autocrine fashion, leading to epithelialization of the cells. (D–F): The induced cells acquire an epithelial phenotype. This change is accom-
panied by the shutting down of the major transcription factors described before (B) and by the acquisition of the epithelial marker E-cadherin. The
cells sequentially form the pretubular aggregate, renal vesicle, C-, and S-shaped bodies, and ﬁnally the mature nephron. The cells derived from the
CM form most of the nephron body (from glomerulus to distal tubule), whereas the UB-derived cells form the collecting duct. Abbreviations: CD,
collecting duct; CM, cap mesenchyme; DT, distal tubule; PECs, parietal epithelial cells; PT, proximal tubule; UB, ureteric bud.
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and replenish epithelial cell types within the nephron. Theoreti-
cally, the nephron stem/progenitor pool can be differentiated
from pluripotent cells, sorted out from the developing kidney,
reverted or dedifferentiated from adult kidney cells, or transdif-
ferentiated from nonrenal cells (Fig. 3). However, in light of the
difﬁculties in locating such cells, especially in humans, utilizing
nonspeciﬁc extrarenal stem cells should be considered. For
example, hematopoietic stem cells (HSCs), endothelial progeni-
tor cells (EPCs)/hemangioblasts, and multipotent mesenchymal
stromal cells (MSCs), are stem cells completely devoid of neph-
rogenic potential [21–24], but may enhance the intrinsic repara-
tive capabilities of the kidney. As EPCs/hemangioblasts have
been shown to possess vasculogenic/angiogenic potential in vari-
ous organs, and speciﬁcally in the kidney [21–26], they can
potentially restore the damaged microvasculature and reverse tis-
sue hypoxia. The latter are two crucial factors in the chain of
events leading to kidney ﬁbrosis and CKD, and if restored by
cell therapy may in turn heal nephron epithelia [27].
Therefore, both renal and nonrenal stem cells can be uti-
lized for kidney repair potentially operating via differentia-
tion-dependent (Fig. 4A) and differentiation-independent
mechanisms (Fig. 4B), respectively. Although we hypothesize
that a combination of the two approaches might be the opti-
mal way of using stem cells for kidney regeneration, this
review focuses on the ﬁrst approach, summarizing the options
for obtaining genuine renal stem/progenitor cells.
DIFFERENTIATION OF RENAL
PROGENITORS FROM PLURIPOTENT STEM
CELLS
Pluripotent mouse and human embryonic stem cells (ESCs)
and induced pluripotent stem (iPS) cells can theoretically give
rise to all cell types in the body, and therefore carry renal
potential. In fact, both undifferentiated and differentiated renal
tissue has been observed in teratomas induced in immunodeﬁ-
cient mice after mouse and human ESCs injection [28, 29].
However, there are several major limitations to the use of
ESCs for kidney regeneration. The ﬁrst issue regards the ethi-
cal, political, and religious problems surrounding the use of
cells derived from early embryos. In addition, a major con-
cern is the mal-differentiation of the cells into unwanted tis-
sues or even the formation of teratomas (see, e.g., Supporting
Information Fig. 1).
To avoid this danger, one must direct the cells to a state
of differentiation that will on the one hand provide them with
the potential to regenerate mature kidney cells of various
types and on the other hand prevent mal-differentiation. This
can be achieved by the controlled activation of the correct
network of nephric transcription factors (see above, Develop-
mental nephrology). Unfortunately, attaining this exact state
of differentiation in vitro has proven to be quite difﬁcult.
Many attempts have been made to induce pluripotent cells in
this manner, applying both growth factor combinations [bone
morphogenetic protein (BMP)/Activin/Retinoic acid] and
genetic approaches [30–36]. However, most differentiation
studies, even after successfully inducing renal lineage genes,
failed to pinpoint the exact stage in nephrogenesis (IM, MM,
CM) to which ESCs were differentiated along the renal line-
age. In addition, analysis of the induced cells in functional in
vivo models is lacking from most reports, in sharp contrast to
human ESCs-derived central nervous system or cardiac pro-
genitors tested in relevant disease models [37, 38]. An excep-
tion is described in a report on beneﬁcial effects of murine
ESCs in a genetic mouse model of Alport syndrome [39],
where undifferentiated ESCs injected into Col4a3-deﬁcient
mice signiﬁcantly improved renal function and histology.
However, because the authors used undifferentiated ESCs
cells rather than ESCs-derived renal progenitors, their ﬁndings
are limited to translation.
Figure 2. SIX2 immunostaining in human fetal kidney: SIX2, playing
a major role in the self-renewal of the nephron’s stem/progenitor cells,
is seen here localizing to the MM, predominantly to the cap mesen-
chyme (arrows), and also to some tubular derivatives (arrowheads). This
corresponds to the ﬁndings in mice [15], where it was shown that by
15.5 days postcoitum, SIX2 expression is restricted to the cap mesen-
chyme and early pretubular aggregates. SIX2 expression ceases 34
weeks postgestation in humans and in the immediate postnatal period in
mice, leading to exhaustion of the stem cell pool and lack of true regen-
erative capacity (The ﬁgure obtained from [17]).
Figure 3. Regenerating nephrons: The cap mesenchyme cells (red)
are the main players toward the ultimate goal of renal regenerative
medicine and therefore different strategies are envisioned to obtain
these cells or create an equivalent population of cells with nephro-
genic potential: differentiation from pluripotent cells (ESCs or iPS
cells), sorting of these cells from human fetal kidneys and de-differ-
entiation via genetic reprogramming of adult kidney cells. Abbrevia-
tions: CM, cap mesenchyme; ESCs, embryonic stem cells; iPS,
induced pluripotent stem cell; UB, ureteric bud.
Pleniceanu, Harari-Steinberg, Dekel 1651
www.StemCells.comDeﬁning human ESC-derived renal progenitors, assess-
ment of their repopulation ability and their in vivo function is
especially important as this could ultimately pave the way to
utilization of human iPS cells as an unlimited source of cells
for renal regeneration or modeling of human disease in which
renal progenitors are perturbed (e.g., renal dysplasia). A major
advantage of ESCs-derived renal progenitors is their being au-
tologous rather than allogeneic [40], a fact that would circum-
vent many of the ethical issues surrounding the use of ESCs.
ISOLATION OF RENAL PROGENITORS FROM
DEVELOPING KIDNEYS
As nephrogenesis progresses, the relative proportion of the
nephrogenic zone decreases. However, due to the fact that stem
cells are present in the embryonic kidney until relatively late in
gestation, can be exploited for their isolation, making the fetal
kidney an attractive source for isolation and utilization of tis-
sue-speciﬁc stem cells [17, 41]. Three main approaches have
emerged for this purpose: (a) Transplantation of whole embry-
onic kidneys or fetal tissue including of human origin (dis-
cussed elsewhere [4–6, 41]). (b) Transplantation of heterogene-
ous populations of fetal cells. (c) Transplantation of speciﬁc
renal embryonic stem/progenitor cell populations.
Heterogeneous Fetal Kidney Cells
Encouraging results regarding the use of cells from develop-
ing kidneys came from a report demonstrating that transplan-
tation of a heterogeneous population of dissociated E14.5 and
E17.5 rat fetal kidney cells under the kidney capsule lead to
the creation of renal structures, and had beneﬁcial effects on
kidney function in a 5/6 nephrectomy model of kidney injury
[42]. The same group also showed [43] that similarly to
whole organ transplants [4], the gestational age of cells to be
transplanted has to be chosen carefully, as early fetal kidney
(E14.5) cells differentiated to nonrenal tissues, whereas cells
from later gestational stages showed poor ability to form kid-
ney structures. Kim et al. [44] recently showed that E17.5 rat
fetal kidney cells were able to reconstitute kidney tissues only
when cultured through passage one, whereas P2 cells experi-
enced proliferation arrest and apoptosis, leading to poor re-
generative potential in vivo. This ﬁnding underscores the im-
portance of deﬁning culture conditions that will minimize
cellular stress and enable cell expansion to obtain clinically
relevant amount of cells.
Isolated Populations of Embryonic Kidney
Progenitors
Few attempts have been made to characterize and use speciﬁc
progenitor/stem populations from the developing kidney.
Lazzeri et al. [45] relied on the previously reported adult
parietal epithelial multipotent progenitors (APEMP), charac-
terized by the expression of CD24 and CD133 [46]. Based on
the assumption that these putative adult progenitors are a rem-
nant of a similar embryonic population, the same
CD24þCD133þ phenotype was used to sort out cells from
human embryonic kidney. It was demonstrated that this popu-
lation initially localizes to the MM, representing 35%–50% of
kidney cells, gradually decreasing in size and becoming re-
stricted to the urinary pole of the Bowman capsule, possibly
Figure 4. Two strategies for kidney repair after injury: (A): Truly committed renal stem cells (blue) harbor nephrogenic potential and contribute
to kidney regeneration via engraftment into damaged tubuli and differentiation into tubular cells (left: blue-green tubular cells that originated
from stem cells) and also by the creation of new nephrons (neo-nephrogenesis; right: cells in the new tubule originate from the stem cells and
are therefore all blue-green). (B): Various extrarenal stem cells (HSCs, MSCs, EPCs) can assist kidney repair through different paracrine effects,
possibly leading to the restoration of the damaged microvasculature, thereby allowing the surviving tubular cells to proliferate and reconstitute a
functioning tubule (all cells in the repaired tubule are green, originating from the surviving cells). Abbreviations: EPC, endothelial progenitor
cell; HSC, hematopoietic stem cell; MSC, mesenchymal stromal cell.
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tracing was not performed and therefore the association
between the adult and embryonic populations has not yet
been validated. Importantly, these cells incorporated into
tubules of SCID mice with glycerol-induced acute renal fail-
ure and differentiated into various types of renal cells.
Identiﬁcation of Renal Stem/Progenitor Markers for
Cell Selection Strategies
The fact that speciﬁc surface markers on stem/progenitor cells
in the kidney have not yet been identiﬁed hampers the identi-
ﬁcation of these cells in the developing kidney [47].
One approach to identify surface markers is through the
use of global gene expression analysis, which in the case of
murine embryonic kidney has identiﬁed CD24a (different
from the human CD24) and Cadherin11 as MM surface
markers [48].
To look for such markers in the human kidney, we ana-
lyzed the developing human kidney concomitant with the pe-
diatric renal malignancy Wilms’ tumors (WT) using microar-
rays [49]. WT results from differentiation arrest of embryonic
progenitor cells committed to the nephric lineage accumulat-
ing in the tumor as undifferentiated blastema. Nevertheless,
because the differentiation arrest is only partial, differentiated
epithelial (tubular-like) and stromal elements are also
observed in the tumor [50].
To circumvent this heterogeneous appearance, we serially
propagated WT xenografts in mice. As a result, the progenitor
blastema expanded at the expense of differentiated elements, cre-
ating stem-like tumors [18]. We hypothesized that overlapping
overexpressed genes in WT-stem like tumors and developing
human kidneys could serve as embryonic renal stem cell
markers. Indeed, gene analysis uncovered a renal stemness signa-
ture set that included the nephron ‘‘progenitor’’ genes (PAX2,
EYA1, WT1, SIX1, SALL1,a n dCITED1), HOX genes, WNT path-
way and Polycomb group genes, and a limited number of surface
markers (neural cell adhesion molecule 1 [NCAM1][ CD56],
poly-sialated neural cell adhesion molecule 1 [PSA-NCAM1],
FZD7, FZD2, DLK1, ACVRIIB,a n dNTRK2) [51] (Fig. 5).
These surface markers were exploited to deﬁne putative
malignant renal stem/progenitor cells in primary WT cultures
marked by NCAM1 but not CD133 [52], and they were also
comprehensively characterized in the human fetal kidney to
determine their relevance in pinpointing the human renal
stem/progenitor cell pool and enabling its isolation via cell
selection strategies [52]. Using this approach, we showed that
immunoselection of cells from the human fetal kidney accord-
ing to a combination of NCAM1 and EpCAM (CD227) dem-
onstrated consistent overexpression of nephron progenitor
genes, in particular SIX2/OSR1. In addition, high vimentin
and low E-cadherin expression indicated that the cells have
yet to undergo mesenchymal-epithelial transition to differenti-
ated nephron epithelia [52]. Further characterization of iso-
lated nephron progenitor cells is ongoing.
In our study, markers considered universal, such as CD133
and CD24, previously reported to identify renal progenitor cells
in both embryonic and adult kidney [45, 46], appeared mostly
Figure 5. Strategy for the identiﬁcation of human renal stem/progenitor markers. (A): Histological appearance of normal fetal kidney. (B): His-
tological appearance of primary WT. WT arises from multipotent renal embryonic precursors that undergo partial differentiation arrest, leading to
a tri-phasic appearance of undifferentiated blastema (b) that resembles the MM, as well as differentiated tubular epithelial (e), and stromal (st)
elements. (C): Establishment of WT-xenografts (Xn). Primary WT were implanted into SCID mice and then serially propagated, eventually lead-
ing to enrichment of stem/progenitor cells (blastema) at the expense of differentiated elements (seen in [D]). (E): Renal ‘‘stemness’’ markers are
those elevated in microarrays of both stem-like WT-xenografts and human fetal kidneys, but not renal cell carcinoma or adult kidneys. Abbrevia-
tions: AK, adult kidney; C, C-shaped body; FK, fetal kidney; G, glomerulus; MM, metanephric mesenchyme; RCC, renal cell carcinoma; S, S-
shaped body; WT, Wilms’ tumor.
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among human fetal kidney cells. Therefore, the combination of
these two markers is not likely to enrich a renal progenitor phe-
notype. Similarly, using an elegant transgenic mouse model, in
which the endogenous promoters of CD133 drive the expression
of the reporter gene lacZ, and by immunohistochemical staining
of mouse and human specimens, Shmelkov et al. [53] showed
that CD133 expression in epithelial tissues is not restricted to
stem or progenitor cells, but rather ubiquitously expressed on
differentiated colonic epithelium in both mice and humans. To
validate these results, the researchers examined expression of
the lacZ reporter in the adult kidney, an organ previously
reported to have large numbers of CD133
þ cells [54], and
found robust CD133 expression.
Thus, areas in the adult kidney previously reported to con-
tain renal stem cells [45, 46, 55, 56] are not necessarily rem-
nants of the embryonic renal progenitors but rather contain dif-
ferentiated cells with proliferating and even clonogenic
capacities, as recently shown for differentiated pigmented cili-
ary epithelial cells, initially identiﬁed as retinal stem cells [57].
Clonogenic Assays
An alternative to the initial step of stem cell isolation via sort-
ing according to speciﬁc surface markers takes advantage of
the fact that stem cells are highly clonogenic [58]. This
approach, which starts from heterogeneous not enriched cell
populations, requires assay systems that allow analysis of a
single cell culture, as in the case of the neurosphere method
for neural stem cells and the colony assay for hematopoietic
progenitors [59]. Osafune et al. [60] set up an assay using
Wnt4 as an inductive signal, which could identify and charac-
terize progenitor cells with multipotent differentiation poten-
tial from uninduced MM which could be used in the future
for other cell sources. They found that only cells strongly
expressing Sall1, isolated from Sall1-GFP mice, formed colo-
nies that partially reconstituted a three-dimensional (3D) kid-
ney structure, which contains glomeruli- and tubule-like com-
ponents in an organ culture setting. This assay, however, has
not yet been used for human kidneys.
In sum, renal progenitors isolated from the developing
human kidney represent a promising source for allogeneic re-
nal regeneration. Although methods to precisely deﬁne and
isolate progenitors are currently being developed, selective
culture conditions remain to be deﬁned to enable retention of
full developmental and regenerative potential upon expansion.
ISOLATION OF RENAL PROGENITORS FROM
DEVELOPED KIDNEYS
Kidney Stem Cells in the Adult—Myth or Reality?
Many adult tissues are considered to harbor cells that self-
renew and differentiate to form clones of stem, progenitor,
and mature cells of the organ, ﬁtting within the criteria of tis-
sue-speciﬁc multipotential stem cells [61]. Some examples are
the hematopoietic system, the skin, and the intestine [62–64].
In contrast to these rapidly cycling organs, the kidney has
a low rate of cell turnover under steady-state conditions [58],
and its regenerative capacity is limited. To date, there is no
deﬁnite evidence for the existence in the adult kidney of a
cell that ﬁts within this deﬁnition. A kidney stem cell should
be capable, at the clonal level, on the one hand to self-renew
and differentiate into the nephron’s cell types, and on the
other hand contribute to renal repair by localizing and differ-
entiating at sites of injury.
Disconnecting Organogenesis and Regeneration
As discussed earlier, on completion of nephrogenesis, the
MM/CM self-renewing renal progenitor population is entirely
exhausted and therefore no progenitor population with neph-
rogenic potential similar to the CM exists in the adult. In this
context, Hartman et al. [20] demonstrated in mice complete
loss by postnatal day 3 of the CM. Interestingly, Humphreys
et al. [65] not only showed lack of expression of the CM
marker gene Six2 in healthy adult mice kidneys, but also
excluded the reactivation of this gene on the induction of is-
chemic kidney damage. These ﬁndings suggest that the CM
population is not re-established postinjury by recapitulation of
the developmental genetic pathways.
It appears therefore, that renal repair in the adult is estab-
lished through replacement of necrotic tubular cells in surviv-
ing nephrons and not by the formation of new nephrons. A
strong case is suggested for the replacement of tubular cells
by proliferation of other differentiated tubular cells. This is,
for example, the recognized mechanism in the pancreas [66].
Vogetseder et al. explored this mechanism during normal kid-
ney homeostasis in the S3 segment of rats [67–69] and found
that cycling and noncycling cells were both differentiated
cells and that most tubular cells divide or enter the cell cycle
in a period of 2 weeks, suggesting that a potential for prolifer-
ation exists in most, if not all cells of the S3 segment. It was
shown that a large proportion of tubular cells are in the G1
phase, and that quiescent cells subjected to a mitotic stimulus
re-enter the cell cycle, implying that tubular cells, many of
which are in the G1 phase, are ready to respond to injury
with a rapid proliferative response. In addition, it was shown
in the ischemic kidney that the replacement of tubular cells
involves dedifferentiation and proliferation of the surviving
tubular cells [70, 71]. Thus, both during normal kidney turn-
over and after damage, a valid option is replacement by
mature tubular cells of their necrotic partners.
However, over the past few years, several groups have
isolated from the adult kidney different cell populations har-
boring progenitor potential using various methodologies.
The question that now arises is ‘‘what have we been iso-
lating?’’ Various explanations, listed below and summarized
in Figure 6, may account for this discrepancy.
Isolation of a Resident Progenitor Rather Than an Intrinsic
Cell Type. Resident progenitors are deﬁned as cells that do
not originate from the MM and localize to the kidney’s inter-
stitial space such as bone marrow-derived cells. Resident pro-
genitors are less likely to be relevant to kidney regeneration,
as Humphreys et al. [65] demonstrated by lineage tracing that
the cells responsible for tubular regeneration after ischemia
are of tubular origin, thereby excluding an extrarenal source.
An example for such a putative resident progenitor population
is the renal MSCs.
MSCs, once hypothesized to be responsible for the home-
ostasis of adult mesenchymal tissues [72], are now considered
a subpopulation of perivascular cells (or pericytes), residing
in virtually every tissue [73–75]. MSCs probably contribute
by recruitment from their perivascular niche to sites of injury,
and by secretion of bioactive molecules, thereby establishing
a regenerative microenvironment [74]. As blood vessels and
pericytes vary among tissues, it is expected that MSCs from
diverse tissue sources are also different [76]. Indeed, recent
studies [77–79] conﬁrmed this assumption.
It is therefore possible that each organ contains its own
speciﬁc population of resident MSCs. For example, Da Silva
Meirelles et al. [80] showed that long-term MSC cultures
could be established from virtually every murine tissue
1654 Kidney Stem/Progenitor Cellsincluding total kidney and kidney glomeruli [77]. Further-
more, MSC populations have been isolated from various fetal
and adult human tissues [73], including the kidney [56].
Isolating an Intrinsic Stromal Progenitor Cell. The devel-
oping kidney contains at least two speciﬁc progenitor popula-
tions [10], that is, the Six2þ nephron progenitors and the
Foxd1þ stromal progenitors, which represent mutually exclu-
sive progenitor compartments. Remnants of the latter popula-
tion in the adult kidney should be relatively easy to clone,
passage, expand, and differentiate along mesoderm lineages in
adhesive cultures, similarly to other stromal populations.
Importantly, the Foxd1þ stromal population does not give
rise to nephron epithelia [65] and lacks nephrogenic potential.
Recently, it has been demonstrated that interstitial cells,
pericytes, residing within the adult kidney, are derivatives of
the embryonic kidney’s Foxd1þ stromal population, account-
ing for most of the myoﬁbroblasts formed during renal ﬁbro-
sis [81]. This ﬁnding demonstrates that interstitial cells do not
contribute to tubular regeneration, and might even negatively
affect the repair process.
Isolating a Fully Differentiated Cell Type with Some ‘‘Stem/
Progenitor’’ Properties. Although shown to posses progeni-
tor properties, it is possible that some of the populations iso-
lated were in fact differentiated cells. Several facts support
this notion.
First, adult differentiated epithelial cell types have been
shown to possess clonogenic and self-renewing capabilities
leading to their possible misinterpretation as stem cells/pro-
genitors [57].
Second, ex vivo growth conditions of cells may result in a
nonspeciﬁc phenotypic switch of differentiated epithelial cells
during epithelial-mesenchymal transition (EMT). Although
these cells may show enhanced proliferation and migration
and appear in a progenitor state, their nature is mostly ﬁbro-
blast/mesenchymal-like, lacking functional relevance [82].
A third reason for this possible misinterpretation is the
use of surface markers or functional parameters for isolation
that overlap with those of differentiated cell types or that
actually mark only differentiated cells. Examples of such cell
markers include ‘‘universal’’ stem cell markers such as
CD133, CD24, Sca-1, and c-Kit, which have all been shown
to be heavily expressed in differentiated epithelia, including
renal epithelia [52–54, 83–85]. Examples of overlapping func-
tional parameters are those used for HSC isolation (label
retention and dye efﬂux capacity) that do not discriminate
between progenitors and differentiated cells in other organs
[58].
Fourth, the lack of appropriate controls for an alleged pro-
genitor cell fraction can also lead to confusion. Analysis of
expression levels of pluripotency or renal developmental
markers, clonogenicity, multipotentiality, and in vitro and in
vivo differentiation potential in a speciﬁc cell type are irrele-
vant if not compared with a cell not expressing the alleged
progenitor phenotype, demonstrating advantageous properties
or function.
Renal potential should be inherent to the biology of a re-
nal stem cell. Clearly, lack of a robust in vitro assay to ana-
lyze nephrogenic potential at the single cell level (as achieved
by limiting dilution), as opposed to the often performed mes-
enchymal tri-lineage (adipocytes, chondrocytes, and osteo-
blasts) differentiation assay relevant for MSCs (but not to re-
nal progenitors), limits the exclusion of differentiated cells
and the inclusion of a bona ﬁde renal stem cell. For such an
assay, developmental cues driving nephrogenesis, as stated
earlier, are likely to be relevant.
In addition, although in vivo renal potential can be studied
in models of renal damage (acute and chronic) or preferably
in models of metanephric development in which the microen-
vironment can support, at least in part, differentiation, one
must exclude cell fusion to establish unequivocal renal
potential.
The Kidney Harbors a Progenitor Population That May
Function Through Genetic and Differentiation Pathways
Other Than the Ones Active During Embryonic
Nephrogenesis. A population with a more restricted poten-
tial than the CM (e.g., a progenitor cell type for proximal tu-
bular cells) may exist. This option might be supported by the
ﬁnding that many developmental genes are upregulated after
kidney damage [49, 51, 86, 87], indicating the possibility that
partial recapitulation of development might occur. However,
such populations might be too small to elicit measurable
regeneration and assist in renal repair, leading to two scenar-
ios for clinical translation.
The ﬁrst is in vitro expansion with risks of cell differen-
tiation or mal-differentiation including acquisition of muta-
tions and possible malignant transformation.
Alternatively, inducing proliferation of progenitor cells
within their native niche in the kidney via delivery of soluble
factors/drugs or other cell types is an option carrying the in-
herent advantage of sparing the patient a renal biopsy. An
example for such cells is MSCs, as one of the presumed
mechanisms for their paracrine effect on the kidney is recruit-
ment of local stem cells [47].
Summarizing the above arguments, a list of reports identi-
fying cells with progenitor potential in the adult kidney are
presented (Table 1 and Supporting Information).
REPROGRAMMING RENAL PROGENITORS
As discussed previously, the current body of evidence
strongly suggests that no residual progenitor population of the
CM resides in the adult kidney, limiting its regenerative
capacities [10]. Thus, instead of investing efforts in the
Figure 6. Possible explanations for the isolation of progenitor cells
from developed kidneys. (1) and (2): Isolation of resident progenitors,
for example, kidney MSCs (1, blue) or hemato-vascular progenitors
(2, pink). (3): Isolation of a stromal progenitor cell (brown). (4): Iso-
lation of a fully differentiated cell type (green) that acquires some
progenitor properties on in vitro culturing (demonstrated by the transi-
tion in the culture dish into an orange cell type). (5): Isolation of tu-
bular progenitors with a more restricted potential (orange).
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to artiﬁcially create CM and nephron progenitors from mature
cells, maintaining the advantage of an autologous cell source.
Because few attempts, if any, have been made to use this
strategy for kidney regeneration, we will focus on general
principles that, in the future, could be used to generate
reprogrammed cells for kidney repair.
The consensus held today is that under physiologic condi-
tions, the fully differentiated state of a cell in the adult is per-
manent, and therefore reprogramming must be forced on cells
[110]. Furthermore, early studies showing cellular plasticity in
adult stem cells have been challenged [111]. Nonetheless, by
applying experimental tools, today, biology is able to force
cells to switch from one type to another. For instance, com-
plete dedifferentiation into pluripotency [112–114] or transdif-
ferentiation between different types of cells, whether differen-
tiated or stem cells [115–118] has been reported. Thus, any
cell can probably be reprogrammed into any another type of
cell, given expression of the right transcriptional network.
Similar to any reprogramming protocol, when trying to
achieve renal reprogramming, a few important questions must
be answered.
Which Transcription Factors Are Relevant?
It has been demonstrated [112, 115, 116] that a limited num-
ber of transcription factors introduced into cells is capable of
activating the full transcriptional machinery necessary for
converting cell fate. Many examples of reprogramming relied
on re-expression of developmental genes [119–121].
In the kidney, the genes to be activated depend on the
identity of the cells we are trying to create. Will we be trying
to achieve mature, functional cells (maybe in situ [115]) or
rather a progenitor cell that following differentiation will
achieve neo-nephrogenesis in the adult? The latter option
seems preferable because unlike other organs (e.g., pancreatic
b-cells), the kidney relies on the orchestrated function of vari-
ous cell types within a speciﬁc 3D structure.
Therefore, kidney regeneration will probably require a
multipotent cell population capable of replenishing the full
spectrum of cells. If this is the case, what is the speciﬁc em-
bryonic population we are looking for? The answer to this
question is not trivial, as the kidney sequentially develops
from posterior IM, through MM and CM and up to the fully
developed nephron, each precursor cell type possessing its
own differentiation potential and a typical gene expression
pattern. In addition, different diseases might require different
cell types (podocytes, tubular cells, etc.). A reasonable option
is to reprogram cells into a MM/CM-like state, as this is the
direct precursor tissue of the nephron. Clearly, if this is the
population we are searching for, continuing efforts to decipher
the phenotypical identity of the human renal progenitor popu-
lation within the MM/CM are crucial.
Which genes are relevant? The molecular mechanisms
governing kidney development, intensively investigated dur-
ing the last 20 years, enable us to wisely choose the appropri-
ate reprogramming factors. Although numerous genes regulate
kidney development and cell lineages [10], those exhibiting a
clear knockout phenotype are probably best suited for reprog-
ramming (including Osr1, Lim1, Pax2/Pax8, Wt1, Foxd1,
Hox11, Six1/Six2, Sall1, and Eya1 [14, 91, 122–129]). This
list can be narrowed, as done recently by Zhou et al. [115],
by testing the candidate factors in different combinations until
the right one is found to induce optimal reprogramming.
Additional Augmentation Techniques for Reprogramming
Are Brieﬂy Covered in the Supporting Information.
Which Cell to Reprogram?
The second aspect of reprogramming is the choice of cells to
be reprogrammed.
Undoubtedly, some cell types are better candidates than
others, with the main criterion being developmental proximity
between the cell types [110], as this reﬂects the differences in
the epigenome that will have to be encountered in order to
activate the correct set of genes. In this case, good candidates
might be adult kidney epithelia or, if identiﬁed, uni-potential
Table 1. Methods used to isolate progenitors from the adult kidney (see Supporting Information for details)
Method Localization Pitfalls/Remarks References
Isolation of slow-cycling
cells (‘‘Label retention’’)
-Tubules -Slow cycling cells are not necessarily stem
cells (88–90)
91–95
-Interstitium of renal papilla -All kidney cycling cells are at the same
degree of differentiation (56)
Isolation of the kidney
Side- Population
Mostly in proximal tubules -Heterogeneous cell population 96–101
-Unclear efﬁciency in vivo
Speciﬁc culture conditions
(MRPCs)
? -No functional improvement in IRI model 102
-Inability to prospectively isolate progenitors
Isolation of highly
proliferative cells
S3 segment of proximal
tubule progenitors
-Unclear efﬁciency in vivo 103
-Inability to prospectively isolate
Surface marker expression
(CD133þ CD24þCD133þ,
and Sca-1þLin )
-Interstitium (CD133þ
and Sca-1þLin-)
-Therapeutic mechanism unclear (renal dif-
ferentiation vs. humoral) or not tested
(Sca-1þ)
34, 45
-Urinary pole of Bowman’s
capsule
(CD24þCD133þ)
-Markers are also heavily expressed on dif-
ferentiated epithelia Interstitial Sca-1þ or
CD133þ cells probably represent resident
progenitors, possibly renal MSCs.
104–106
Genetic tracing via the
‘‘hemangioblastic’’ marker SCL
Interstitium, probably originating
from the bone marrow
-These cells possibly represent resident hem-
ato-vascular progenitors
107–109
Abbreviations: IRI, ischemia-reperfusion injury; MRPCs, multipotent renal progenitor cells; MSCs, mesenchymal stromal cells; SCL, stem
cell leukemia.
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more developmentally distant cells cannot be excluded.
How to Prove That the Conversion Was Successful?
Finally, the importance of demonstrating a full phenotypic and
functional change into the desired cell type will be discussed.
Unlike nondesirable EMT resulting in a nonspeciﬁc ﬁbro-
blastic phenotype, the induced cell should undergo reverse
nephrogenesis to a mesoderm phenotype. This new cell type
should upregulate the renal progenitor genes, culminating in a
stable progenitor-state amenable to in vitro and in vivo induc-
tive signals, preferably at the clonal level, to preserve nephro-
genic potential. It is prudent to exclude cell fusion and a
hybrid phenotype, that is, upregulation of only a few genes
due to overexpression of potent transcription factors.
CONCLUSION
Reports of kidney stem cell populations in mouse and human
kidneys are met with enthusiasm because of their potential for
cell-based therapies to treat millions of people with renal fail-
ure worldwide. Nevertheless, to date, the presence of a true
adult kidney stem cell remains elusive.
This does not eliminate the possibility of using sorted,
clonogenic, or in vitro expanded populations of adult kidney
cells as cell-based therapies. In addition, a functional beneﬁt
may arise from various cell types lacking nephrogenic
potential.
Efforts should be directed toward replenishment of neph-
rons through isolation of progenitor cells from fetal kidneys,
reprogramming them from adult cells or using differentiated
ESCs/iPS cells.
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